Predictive significance of TCI-R for antidepressant treatment

Med Sci Monit. 2010 Aug;16(8):CR383-8.

Abstract

Background: The aim of this study was to investigate the significance of the Temperament and Character Inventory-Revised (TCI-R) dimensions of personality for prediction of treatment outcome in depressed outpatients during 6 months of antidepressant treatment.

Material/methods: Thirty outpatients were treated for mild or moderate depressive episode, current mild or moderate episode of recurrent depressive disorder or mixed anxiety and depressive disorder (ICD-10). The intensity of depression was assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) at the beginning of treatment and then after the 1st, 3rd and 6th months of treatment. The personality dimensions were assessed by the TCI-R at the same time points as the MADRS. Differences in TCI-R dimensions between treatment responders (> or =50% decrease in MADRS score after 6 months of treatment) and nonresponders (<50% decrease in MADRS score) were compared by repeated measures analysis of variance (ANOVA). Predictive value for the treatment outcome was assessed by Spearman's correlation coefficient.

Results: The predictive significance for treatment outcome (Spearman's correlation coefficient) was identified for reward dependence (RD) (R=-0.44) and harm avoidance (HA) (R=0.46) dimensions. Treatment responders and nonresponders significantly differed (ANOVA) in HA (p<0.05), showing a decrease in total mean HA score only in responders during treatment.

Conclusions: Our findings showed predictive significance of the TCI-R dimensions HA and RD for long-term antidepressant treatment outcome.

MeSH terms

  • Analysis of Variance
  • Antidepressive Agents / therapeutic use*
  • Avoidance Learning / drug effects
  • Character*
  • Depressive Disorder / drug therapy*
  • Humans
  • Personality Inventory*
  • Predictive Value of Tests
  • Psychiatric Status Rating Scales
  • Temperament* / drug effects
  • Treatment Outcome

Substances

  • Antidepressive Agents